02325.HK
Yunkang Group Limited
HKSE · Healthcare · Medical - Diagnostics & Research · CN
HKD 0.47
−4.12%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 540.9M | 601.4M | 711.9M | 891.5M | 3.8B |
| Cost of Revenue | 386.3M | 418.6M | 500.8M | 565.7M | 2.9B |
| Gross Profit | 154.7M | 182.8M | 211.1M | 325.8M | 1.5B |
| Operating Expenses | |||||
| R&D Expense | 50.1M | 51.9M | 57.4M | 61.1M | 94.7M |
| SG&A Expense | 411.3M | 304.7M | 445.0M | 342.5M | 698.7M |
| General & Admin Expense | 168.2M | 186.5M | 264.8M | 191.6M | 386.7M |
| Selling & Marketing Expense | 111.1M | 118.2M | 180.2M | 150.9M | 312.0M |
| Other Expenses | (392.7M) | (206.7M) | 518.1M | 35.9M | 55.8M |
| Total Operating Expenses | 68.6M | 149.9M | 963.1M | 378.4M | 849.2M |
| Cost and Expenses | 454.9M | 568.4M | 1.5B | 944.1M | 3.3B |
| Operating Income (EBIT) | 86.0M | 32.9M | (752.1M) | (52.6M) | 458.6M |
| Non-Operating | |||||
| Interest Income | — | 8.9M | 10.2M | 9.3M | 5.2M |
| Interest Expense | — | 34.9M | 49.3M | 43.6M | 19.9M |
| Net Interest Income | (21.0M) | (26.0M) | (39.1M) | (34.2M) | (14.7M) |
| Other Non-Op Income/Expense | (21.0M) | (26.0M) | (39.1M) | (34.2M) | (15.1M) |
| Non-Operating Income (excl Interest) | (22.5M) | (57.2M) | (10.2M) | (9.3M) | 18.1M |
| EBT (Pre-Tax Income) | 65.1M | 7.0M | (791.2M) | (86.8M) | 443.4M |
| Income Tax Expense | 3.1M | 3.1M | 2.0M | 15.1M | 69.5M |
| Bottom Line | |||||
| Net Income | 60.7M | 2.9M | (791.7M) | (102.3M) | 377.3M |
| Earnings from Cont. Ops | 61.7M | 3.9M | (793.2M) | (101.9M) | 373.9M |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | 60.7M | 2.9M | (791.7M) | (102.3M) | 377.3M |
| Per Share | |||||
| Basic EPS | HK$0.10 | HK$0.01 | (HK$1.33) | (HK$0.17) | HK$0.66 |
| Diluted EPS | HK$0.10 | HK$0.01 | (HK$1.33) | (HK$0.17) | HK$0.66 |
| Revenue Per Share | HK$0.89 | HK$1.03 | HK$1.19 | HK$1.46 | HK$6.13 |
| Shares | |||||
| Basic Shares Outstanding | 611.0M | 585.3M | 595.9M | 611.1M | 613.2M |
| Diluted Shares Outstanding | 585.3M | 585.3M | 595.9M | 611.1M | 613.2M |
| Profitability Metrics | |||||
| EBITDA | 113.8M | 122.7M | (668.5M) | 25.1M | 569.5M |
| D&A | 5.3M | 32.5M | 73.4M | 68.3M | 129.1M |
| EBIT | 108.5M | 90.2M | (741.9M) | (43.3M) | 440.4M |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026